A strategic partnership has propelled West Chester-based Verrica Pharmaceuticals into the Japanese market, as Torii Pharmaceutical Co. Ltd. launches YCANTH for molluscum contagiosum. The approval, granted in September 2025, marks an important step in offering treatment options to patients suffering from this skin condition.